<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2883">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03069365</url>
  </required_header>
  <id_info>
    <org_study_id>M16-127</org_study_id>
    <secondary_id>2016-004182-60</secondary_id>
    <nct_id>NCT03069365</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment</brief_title>
  <acronym>Expedition-5</acronym>
  <official_title>A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Renally-Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (EXPEDITION-5)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 3b, open-label, non-randomized study will evaluate the efficacy and safety of
      Glecaprevir/Pibrentasvir (GLE/PIB) for 8, 12, or 16 weeks in in participants with chronic
      hepatitis C virus (HCV) genotype (GT) 1 - 6 infection with or without compensated liver
      cirrhosis and with chronic renal impairment in both HCV treatment-naïve and prior
      treatment-experienced participants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2017</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with sustained virologic response 12 weeks post dosing (SVR12)</measure>
    <time_frame>12 weeks after last dose of study drug</time_frame>
    <description>SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) levels less than the lower limit of quantitation (LLOQ) (less than 15 IU/mL) 12 weeks after the last actual dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with HCV on-treatment virologic failure</measure>
    <time_frame>Up to 16 weeks (treatment arm specific)</time_frame>
    <description>HCV on-treatment virologic failure defined as:
Confirmed increase from nadir in HCV RNA defined as confirmed increase of &gt; 1 log10 IU/mL above nadir during treatment; or
Confirmed HCV RNA greater than or equal to 100 IU/mL after HCV RNA less than LLOQ during study drug treatment; or
HCV RNA ≥ LLOQ at the end of treatment with at least 6 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with post-treatment HCV virologic relapse</measure>
    <time_frame>Up to 28 weeks (12 weeks after last dose of study drug)</time_frame>
    <description>Post-treatment virologic failure (Relapse) is defined as:
- Confirmed HCV RNA greater than or equal to LLOQ (defined as confirmed HCV RNA greater than or equal to LLOQ between end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment as planned with HCV RNA less than LLOQ at the end of treatment; excluding participants who have been shown to be re-infected), for participants who completed treatment (defined as study drug duration ≥ 77 days, ≥ 105 days and 103 days for participants allocated to the 8, 12 and 16 week durations, respectively).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hepatitis C Virus (HCV)</condition>
  <arm_group>
    <arm_group_label>Arm A: GLE/PIB for 8 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A: Hepatitis C Virus (HCV) Genotype (GT)1, 2, 4 - 6 participants without cirrhosis who are treatment naïve (TN) or treatment experienced (TE) and HCV GT 3 participants without cirrhosis who are TN treated with Glecaprevir (GLE)/Pibrentasvir (PIB) 300 mg/120 mg once daily (QD) for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: GLE/PIB for 12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B: HCV GT1, 2, 4 - 6 participants with cirrhosis who are TN or TE and HCV GT 3 participants with cirrhosis who are TN treated with GLE/PIB 300 mg/120 mg QD for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: GLE/PIB for 16 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm C: All HCV GT3 participants who are TE will be treated with GLE/PIB 300 mg/120 mg QD for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glecaprevir/Pibrentasvir</intervention_name>
    <description>Film-coated tablet</description>
    <arm_group_label>Arm A: GLE/PIB for 8 weeks</arm_group_label>
    <arm_group_label>Arm B: GLE/PIB for 12 weeks</arm_group_label>
    <arm_group_label>Arm C: GLE/PIB for 16 weeks</arm_group_label>
    <other_name>ABT-493/ABT-530</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant has a positive anti-hepatitis C virus (HCV) antibody (Ab) and plasma HCV
             ribonucleic acid (RNA) greater than or equal to 1000 IU/mL at Screening Visit.

          -  Participant has an estimated glomerular filtration rate (eGFR) less than
             45mL/min/1.73 m^2

          -  Cirrhotic participants only: absence of hepatocellular carcinoma (HCC)

        Exclusion Criteria:

          -  Current HBV or human immunodeficiency virus (HIV) infection on screening tests,
             defined as:

          -  Positive test result at screening for hepatitis B surface antigen (HBsAg) or

          -  HBV DNA less than lower limit of quantification (LLOQ) in participants with isolated
             positive anti-HBc (i.e., negative HBsAg and Anti-HBs), or

          -  Positive anti-HIV antibody (Ab).

          -  Clinical history of acute renal failure in the 3 months prior to screening.

          -  Clinically significant abnormalities or co-morbidities, or recent (within 6 months
             prior to study drug administration) alcohol or drug abuse that could preclude
             adherence to the protocol in the opinion of the investigator.

          -  Receipt of any investigational or commercially available direct acting anti-HCV
             agents other than sofosbuvir.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emily Dumas, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AbbVie_Call Center</last_name>
    <phone>847-283-8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Huntington Medical Foundation /ID# 160653</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tampa General Medical Group, Tampa General Hospital /ID# 159115</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwest Louisiana Nephrology L.L.C. /ID# 160652</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital /ID# 159114</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwell Health, Inc. /ID# 159108</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center /ID# 159112</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Morehead Medical Plaza /ID# 159113</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University /ID# 159754</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania /ID# 159117</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Liver Institute, American Research Corporation /ID# 159111</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Organ Transplant and Liver Centre /ID# 159110</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital /ID# 160600</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital - University Health Network /ID# 160601</name>
      <address>
        <city>Toronto</city>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vancouver Infectious Diseases Centre /ID# 160598</name>
      <address>
        <city>Vancouver</city>
        <zip>V6Z 2C7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>GIRI Gastrointestinal Research Institute /ID# 160599</name>
      <address>
        <city>Vancouver</city>
        <zip>V6Z-2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico P. Giaccone /ID# 160718</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario &quot;Agostino Gemelli&quot; /ID# 160719</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>VA Caribbean Healthcare System (VACHS) /ID# 160754</name>
      <address>
        <city>San Juan</city>
        <zip>00921</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Puerto Rico, School of Medicine /ID# 160755</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Italy</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 30, 2017</lastchanged_date>
  <firstreceived_date>February 28, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ribavirin (RBV)</keyword>
  <keyword>non-cirrhotic</keyword>
  <keyword>treatment naïve</keyword>
  <keyword>interferon (IFN)</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Hepatitis C Virus Genotype</keyword>
  <keyword>Chronic Hepatitis C Virus</keyword>
  <keyword>compensated cirrhosis</keyword>
  <keyword>pegylated interferon (pegIFN)</keyword>
  <keyword>sofosbuvir (SOF)</keyword>
  <keyword>Glecaprevir</keyword>
  <keyword>Pibrentasvir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
